Michael Weichenthal

20PUBLICATIONS
113CO-AUTHORS
Molecular targetsNanotoxicology, health and safetyPredictive and prognostic markersEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 11, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

|Mar 15, 2026
Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Ralf Gutzmer, Michael Weichenthal, Thomas Eigentler

|Feb 27, 2026
COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Michael Weichenthal, Dirk Debus, Lisa Zimmer

|Nov 09, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.

Michael Weichenthal, Joanna Mangana, Iva Gavrilova

|Sep 28, 2023
COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma.

Carola Berking, Elisabeth Livingstone, Dirk Debus

|Sep 20, 2023
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG.

Maximilian Haist, Henner Stege, Friederike Rogall

Pageof 4

Frequent Collaborators

10 joint publications

Selma Ugurel

8 joint publications

Dirk Schadendorf

6 joint publications

Jessica Cecile Hassel

6 joint publications

Ralf Gutzmer